Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE ZIDOVUDINE 150 MG 300 MG TABLETS CO PACKAGED WITH NEVIRAPINE 200 MG TABLETS versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE ZIDOVUDINE 150 MG 300 MG TABLETS CO PACKAGED WITH NEVIRAPINE 200 MG TABLETS versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
Lamivudine/Zidovudine 150 mg/300 mg Tablets Co-packaged with Nevirapine 200 mg Tablets vs LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV-1 reverse transcriptase by competitive inhibition and chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural substrates and causing chain termination. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
One tablet (lamivudine 150 mg/zidovudine 300 mg) orally twice daily, plus one tablet (nevirapine 200 mg) orally once daily for first 14 days, then one tablet (nevirapine 200 mg) orally twice daily thereafter.
One tablet (lamivudine 300 mg; zidovudine 300 mg; efavirenz 600 mg) orally once daily on an empty stomach, preferably at bedtime.
None Documented
None Documented
Lamivudine: terminal half-life 5-7 hours in adults; prolonged in renal impairment. Zidovudine: terminal half-life 1.1-1.3 hours; prolonged to 1.7 hours in renal impairment. Nevirapine: terminal half-life 45 hours (single dose), reducing to 25-30 hours after multiple dosing due to autoinduction.
Lamivudine: 5-7 hours in adults (prolonged in renal impairment). Zidovudine: 0.5-3 hours (terminal half-life), with intracellular active triphosphate half-life ~3 hours. Efavirenz: 40-55 hours (single dose), 10-20 hours at steady state (due to autoinduction), supporting once-daily dosing.
Lamivudine: primarily renal excretion of unchanged drug (approximately 70% within 24 hours) via glomerular filtration and active tubular secretion. Zidovudine: renal excretion (approximately 14% unchanged) and hepatic metabolism to GAZT (glucuronide), with 74% of dose recovered in urine as total zidovudine and metabolites. Nevirapine: 81% of dose recovered in urine (primarily metabolites) and 10% in feces; <5% excreted unchanged in urine.
Lamivudine: renal (approximately 70% unchanged via glomerular filtration and active tubular secretion). Zidovudine: renal (approximately 14% unchanged, major metabolite G-ZDV 60-80% excreted in urine). Efavirenz: hepatic metabolism (CYP2B6, CYP3A4) with fecal (14-34%) and urinary (<1%) elimination.
Category A/B
Category A/B
NRTI
NRTI